Quantification and pharmacokinetics of Taiwanin E methyl ether in rats by liquid chromatography-tandem mass spectrometry.
Feng Qiu, Shujun Fu, Shujun Zhou, Shihai Yang, Meihua Yang
Index: Biomed. Chromatogr. 27(2) , 233-9, (2013)
Full Text: HTML
Abstract
This study firstly describes the development of an accurate and sensitive high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay for the quantification of Taiwanin E methyl ether (TEME) in rat plasma. The assay involved a simple liquid-liquid extraction step with ethyl acetate and a gradient elution using a mobile phase consisting of water containing 0.1% formic acid and acetonitrile containing 0.1% formic acid. Chromatographic separation was successfully achieved on an Agilent Zorbax-C(18) column (2.1 × 50 mm, 3.5 µm) with a flow rate of 0.40 mL/min. The multiple reaction monitoring was based on the transitions of m/z = 379.1 → 320.1 for TEME and 386.1 → 122.0 for buspirone (internal standard). The assay was validated to demonstrate the specificity, linearity, recovery, accuracy, precision and stability. The lower limit of quantification was 0.50 ng/mL in 50 μL of rat plasma. The developed and validated method was successfully applied to the quantification and pharmacokinetic study of TEME in rats after intravenous and oral administration of 1.45 mg/kg TEME. The oral absolute bioavailability of TEME was estimated to be 5.85 ± 1.41% with an elimination half-life value of 2.61 ± 0.55 h, suggesting its poor absorption and/or strong metabolism in vivo.Copyright © 2012 John Wiley & Sons, Ltd.
Related Compounds
Related Articles:
2013-12-01
[Eur. J. Drug Metab. Pharmacokinet. 38(4) , 223-9, (2013)]
Premenstrual syndrome: a single-blind study of treatment with buspirone versus fluoxetine.
2013-03-01
[Arch. Gynecol. Obstet. 287(3) , 469-72, (2013)]
Two weeks of buspirone protects against posthypoxic ventilatory pauses in the C57BL/6J mouse strain
2012-07-31
[Respir. Physiol. Neurobiol. 183(1) , 35-40, (2012)]
Development of oral extended release formulations of 6-hydroxybuspirone.
2012-12-01
[Biopharm. Drug Dispos. 33(9) , 522-35, (2012)]
2013-11-27
[Neurosci. Lett. 556 , 210-5, (2013)]